

SECURITIES AND EXCHANGE COMMISSION

FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: **2013-01-28** | Period of Report: **2013-01-28**
SEC Accession No. [0000810084-13-000003](#)

([HTML Version](#) on [secdatabase.com](#))

REPORTING OWNER

Logomasini Mark

CIK: **1480077**

Type: **4** | Act: **34** | File No.: **000-15360** | Film No.: **13553374**

Mailing Address

20245 SW 95TH AVENUE
TUALATIN OR 97062

ISSUER

BIOJECT MEDICAL TECHNOLOGIES INC

CIK: **810084** | IRS No.: **931099680** | State of Incorporation: **OR** | Fiscal Year End: **1231**
SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address

20245 SW 95TH AVENUE
TUALATIN OR 97062

Business Address

20245 SW 95TH AVENUE
TUALATIN OR 97062
5036928001

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Expires:	02/28/2011
Estimated average burden hours per response	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Logomasini Mark			2. Issuer Name and Ticker or Trading Symbol BIJECT MEDICAL TECHNOLOGIES INC [BJCT]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) CEO/President		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/28/2013					
7180 SW SANDBURG STREET, SUITE 100								
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person <input type="checkbox"/> Form Filed by More than One Reporting Person		
TIGARD, OR 97223								
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Warrant to Purchase Common Stock	\$0.19	12/29/2011		P		39,474		12/29/2011	06/28/2014	BJCT Common Stock	\$ 0	39,474	D	
Warrant to Purchase Common Stock	\$0.19	01/24/2013		D		78,948		01/24/2013	01/24/2013	BJCT Common Stock	\$ 0	0 ⁽¹⁾	D	
Series H Convertible Preferred Stock	\$0.035	01/24/2013		P		3,192,285		01/24/2013	(2)	BJCT Common Stock	\$0.035	3,192,285 ⁽³⁾	D	

Explanation of Responses:

1. Cancellation of Warrants pursuant to Convertible Debt conversion into 8,673 Series H Preferred Stock.
2. No expiration date.
3. Holdings: 11,173 shares of Series H Preferred Stock convertible into 3,192,285 shares of Common Stock.

Signatures

//Christine M. Farrell Attorney-in-Fact for Mark Logomasini//

** Signature of Reporting Person

01/28/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.